RecruitingPhase 3NCT05669833

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients: a Pragmatic Trial (EVOLUTION)

Sponsor

University of Pennsylvania

Enrollment

63 participants

Start Date

Jul 14, 2023

Study Type

INTERVENTIONAL

Conditions

Psoriatic Arthritis

Summary

The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Golimumab and a drug called Guselkumab for people with psoriatic arthritis. The study is currently recruiting participants at 14 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGuselkumab

Guselkumab (GUS) subcutaneous injection

DRUGGolimumab

Golimumab (GOL) subcutaneous injection

Locations(14)

Family Arthritis Center

Loxahatchee Groves, Florida, United States

Healing Rheumatology

Plant City, Florida, United States

Southwest Florida Rheumatology

Riverview, Florida, United States

Parris and Associates

Lilburn, Georgia, United States

University of Massachusetts Chan Medical School

Worcester, Massachusetts, United States

University of Nebraska Medical Center

Omaha, Nebraska, United States

New York University

New York, New York, United States

Cincy Arthritis

Blue Ash, Ohio, United States

Southern Ohio Rheumatology

Wheelersburg, Ohio, United States

Hospital at the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Cumberland Rheumatology

Crossville, Tennessee, United States

Heritage Rheumatology and Arthritis Care

Colleyville, Texas, United States

Texas Arthritis Center

El Paso, Texas, United States

University of Utah

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05669833

Related Trials

A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

NCT0740603544 locations

Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders

NCT071805371 location

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT0688819314 locations

HLA B Leader in Patients With Psoriatic Arthritis

NCT077188151 location

Modifying PEST for Psoriatic Arthritis Screening

NCT0638205130 locations